Navigation Links
ACC Presentation Indicates Interleukin-1 Gene Variants Determine,Increased Risk for Coronary Artery Disease from Oxidized,Phospholipids

er materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, our ability to integrate acquired businesses, our ability to maintain relationships with our important customers, and those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2005 filed with the Securities and Exchange Commission, our quarterly reports on Form 10-Q and other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.

Contact

For Interleukin Genetics:
Paul Voegelin, 781-398-0700


'"/>




Page: 1 2 3

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
3. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
4. Rosetta Genomics to Webcast Presentation at CE Unterberg, Towbin Emerging Growth Opportunities Conference
5. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
10. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
11. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
Post Your Comments:
(Date:12/1/2008)...tCall/ -- GeoVax Labs, Inc.,(OTC Bulletin Board: ...loping,human vaccines for diseases caused by HIV-...ious agents, announced today that the launch of it...n twelve sites across North and South America.,Th... National Institutes of,Health (NIH), and the HIV...
(Date:11/28/2008)...28 German biotech company,Partec ...HIV monitoring and,AIDS patient follow-up diagnos...e year 2008, 2.5 million patient tests have been p...ordable "CyFlow" system, supporting already,more ... introduction of the,Partec innovation, the avera...
(Date:11/26/2008)...utomation and intelligent clinical applications ta... level , , CHICAGO, Ill., Nov. 26 /PRNewswi...ens.com/healthcare ) highlights the ACUSON S2000(...e world,s first multi-use, automated volume breast...y and Annual Meeting of the Radiological Society o...
(Date:11/25/2008)...against expanding statin use broadly in wake of AH...ov. 25 JUPITER, a clinical trial s...r risk of healthy patients with elevated CRP, shou..., according to a national poll directed at health ...n the online poll conducted by medical news site M...
Breaking Medicine Technology:GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Nearly Half of Newly Diagnosed HIV AIDS Cases in Los Angeles County Are Among Latinos 27301 1Nearly Half of Newly Diagnosed HIV AIDS Cases in Los Angeles County Are Among Latinos 27301 2Vista Partners Updates Coverage on Arana Therapeutics 28ASX 3A AAH 3B AIM 3A AAHx 29 Raises Target Price to AU 241 65 8239 1Vista Partners Updates Coverage on Arana Therapeutics 28ASX 3A AAH 3B AIM 3A AAHx 29 Raises Target Price to AU 241 65 8239 2Excess Drinking Shrinks the Brain 27296 1Excess Drinking Shrinks the Brain 27296 23 Michigan Counties Participating in NIH Study of Cardiac Arrest Resuscitation Techniques 27293 13 Michigan Counties Participating in NIH Study of Cardiac Arrest Resuscitation Techniques 27293 2
...-Jun 7, 2007 - Clinical results from a,Phase II st...eadache Society (AHS) annual meeting showed that M...lated peptide (CGRP),receptor antagonist, signific...r dosing compared to placebo, and the relief was,s...ell tolerated in,the study. Responses specific to ...
...07, 2007 /PRNewswire-FirstCall/ --,Mymetics Corpor...ating that the Company,s HIV vaccine elicited neut...mate model. Mucosal IgA,antibodies are considered ...ion by HIV. The data were presented by Sylvain,Fle... an oral,presentation titled, "Without Mucosal Adj...
Other Medicine Technology:Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 2Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 3Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 4Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 5Mymetics' HIV Vaccine Demonstrates First-Ever Production of,Neutralizing IgA Antibodies in Non-Human Primate Model 2Mymetics' HIV Vaccine Demonstrates First-Ever Production of,Neutralizing IgA Antibodies in Non-Human Primate Model 3Mymetics' HIV Vaccine Demonstrates First-Ever Production of,Neutralizing IgA Antibodies in Non-Human Primate Model 4
(Date:12/1/2008)...lergy Friendly, Toy Puppies to the Obama Daughters...ire/ -- Much has been made of President-Elect Obam...rns about his daughter,s asthma and allergies, and...aking a decision. So, in the meantime, the Asthma...ing 2 "asthma & allergy friendly" toy puppies ...
(Date:12/1/2008)...und that the availability of a portable eight-slic... room can significantly increase the number of str...treatment. Results of the study, conducted at Nort...lem, Mass., will be presented today at the annual ...ca (RSNA). , "The hospital,s acquisition of a p...
(Date:12/1/2008)...s that computed tomography (CT) colonography, also...o screen for two diseases at oncecolorectal cancer...dults over age 50. Results of the study will be pr...gical Society of North America (RSNA). , "With C...ectal cancer, we were able to identify patients wi...
(Date:12/1/2008)... As the connection between second-hand smoke and c...islation was passed to reduce such passive smoking...shed in the January 2009 issue of the American Jo...e University of California, San Francisco, Partner...recalibrated the CHD Policy Model to better predic...
Breaking Medicine News(10 mins):Health News:Asthma and Allergy Foundation Helps New First-Dad Keep His First Promise 2Health News:Portable CT increases chance of stroke survival and recovery 2Health News:CT colonography offers 1-stop screening for cancer and osteoporosis 2
...ommonwealth University Massey Cancer Center have d...ns, using small molecules containing platinum, whi...l be beneficial for the researchers to develop new...cer by selectively targeting proteins known as zin...
...-run hospitals across the country were restored to...nti-quota protests following a directive from the ...institutions like AIIMS, MAMC, Lady Hardinge and S...ioning with junior doctors reporting back to duty....
...ve found that an amphetamine-like stimulant has a ...hyperactivity disorder (ADHD) // . A new study un... a drug that is widely used to treat ADHD, appears...sn't as easily distracted by any stimuli from the ...
...ar-old adults in UK revealed that above half of th.../ To make themselves intoxicate, about 18 per cent...ol. About 59 per cent and 43 per cent of people in...24 and 25-34 respectively, and who drank to get dr...
Other Medicine News:Health News:New Research May Be Useful for Developing Drugs for HIV and Cancer 2Health News:Ritalin Could Help In Focussing The Mind 2
All oral and nasal airways are manufactured with smooth, rounded edges for increased patient comfort and safety., ,Portex® offers a broad selection of airways for a variety of clinical applicati
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex
Our soft guedel airway is clear and has a color coded bite block. Airway has a smooth finish and is Latex Free. Recommended for single use. Non-Sterile.
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex
Medicine Products: